Anmelden Kostenlos registrieren

Last updated: 20 June 2024 at 4:12pm EST

Carsten Boess Net Worth




The estimated Net Worth of Carsten Boess is at least $1.75 Million dollars as of 25 April 2011. Mr. Boess owns over 41,296 units of Rocket Pharmaceuticals Inc stock worth over $1,146,310 and over the last 20 years he sold RCKT stock worth over $263,138. In addition, he makes $337,045 as Independent Director at Rocket Pharmaceuticals Inc.

Mr. Boess RCKT stock SEC Form 4 insiders trading

Carsten has made over 5 trades of the Rocket Pharmaceuticals Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 41,296 units of RCKT stock worth $332,020 on 25 April 2011.

The largest trade he's ever made was exercising 47,296 units of Rocket Pharmaceuticals Inc stock on 29 March 2011 worth over $380,260. On average, Carsten trades about 4,641 units every 64 days since 2005. As of 25 April 2011 he still owns at least 60,237 units of Rocket Pharmaceuticals Inc stock.

You can see the complete history of Mr. Boess stock trades at the bottom of the page.





Carsten Boess biography

Carsten Boess serves as Independent Director of the Company. He previously served as Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, a publicly-traded biotechnology company and as Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation from 2011 until the company’s acquisition by Alexion Pharmaceuticals in 2015. Prior to his role at Synageva, Mr. Boess served in multiple roles with increasing responsibility for Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance for Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva-based World Wide Executive Finance Management Team while at Serono. Mr. Boess was also Chief Financial Officer at Alexion Pharmaceuticals and was a finance executive at Novozymes of North America and Novo Nordisk in France, Switzerland and China. He is also a board member of Avidity Biosciences, a privately held biopharmaceutical company, and Achilles Therapeutics, also a privately held biopharmaceuticals company. Mr. Boess received a Bachelor’s degree and Master’s degree in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark.

What is the salary of Carsten Boess?

As the Independent Director of Rocket Pharmaceuticals Inc, the total compensation of Carsten Boess at Rocket Pharmaceuticals Inc is $337,045. There are 10 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.



How old is Carsten Boess?

Carsten Boess is 53, he's been the Independent Director of Rocket Pharmaceuticals Inc since 2016. There are 6 older and 11 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.

What's Carsten Boess's mailing address?

Carsten's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.

Insiders trading at Rocket Pharmaceuticals Inc

Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten und Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.



What does Rocket Pharmaceuticals Inc do?

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.



What does Rocket Pharmaceuticals Inc's logo look like?

Rocket Pharmaceuticals Inc logo

Complete history of Mr. Boess stock trades at Alexion Pharmaceuticals, Insulet, Rocket Pharmaceuticals Inc, Kiniksa Pharmaceuticals International Plc und Avidity Biosciences

Datum
#
Unternehmen
 Insider
Trans.
Transaktion
 Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
25 Apr 2011 PODD Insulet Corporation Carsten Boess
Finanzvorstand
 Optionausübung 41,296 $8.04 $332,020
25 Apr 2011
60,237 ↗
18 Apr 2011 PODD Insulet Corporation Carsten Boess
Finanzvorstand
 Optionausübung 6,000 $8.04 $48,240
18 Apr 2011
24,941 ↗
29 Mar 2011 PODD Insulet Corporation Carsten Boess
Finanzvorstand
 Optionausübung 47,296 $8.04 $380,260
29 Mar 2011
30,841 ↗
24 Mar 2011 PODD Insulet Corporation Carsten Boess
Finanzvorstand
 Optionausübung 47,296 $8.04 $380,260
24 Mar 2011
34,841 ↗
27 Jun 2005 ALXN Alexion Pharmaceuticals Inc. Carsten Boess
Vice President und CFO
 Verkauf 11,250 $23.39 $263,138
27 Jun 2005
0 ↗


Rocket Pharmaceuticals Inc executives and stock owners

Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include: